Floatz logo

Fimepinostat

Recurrent Malignant Glioma

Sabine Mueller, MD, PhDSmall moleculeEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

108 Active assets in the Recurrent Malignant Glioma cohort.

Asset / SponsorPhaseRating
Irinotecan
Kailin Yang, MD, PhD
Phase 2BB
Marizomib
Aadi Bioscience, Inc.
Phase 2BB
Valaciclovir
Trogenix ltd
Phase 2BB
Valproic Acid
Virginia Commonwealth University
Phase 2BB
DISODIUM 4-((TERT-BUTYLIMINO)METHYL)BENZENE-1,3-DISULFONATE N-OXIDE
Oblato, Inc.
Phase 2BB

View all 50 →

Same molecule, other indications

Fimepinostat is also rated in:

relapsed/refractory diffuse large B-cell lymphomaDormant
CC
Indicative ·
47 / 100
View asset →
high-grade B-cell lymphoma double-hit/triple-hitDormant
CC
Indicative ·
47 / 100
View asset →
high grade B-cell lymphomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →